I just saw a patient with UNSTEADY WALK & alcohol-related liver disease. I always assess these 4 factors: • Sarcopenia • Peripheral neuropathy • Vitamin B12 deficiency • Cerebellar atrophy This figure summarizes my approach:

🏀 Next up: The NEW MASLD Treatment Era @JazminMexia explores combination metabolic therapy, real-world resmetirom use, and quality of life. New treatments are reaching patients—but what do the results show? Thread 👇 #HepMadness2026

What are the controversies we need to solve that face US patients with cirrhosis? Join us in Miami in January ACES-Summit.org Organized by O’Leary, @serperm, @JasmohanBajaj, and myself, we hope you join us to build better evidence and better strategies for our patients

⏰ Only 5 days until #HepMadness2026 brackets lock! 16 themes. One champion. 🏆 Have you made your picks yet? Submit your bracket here: tourneytopia.com/aasld/hepma…

🏀 Next up: AI in the Clinic and at the Bedside @drnakulganju explores AI that finds missed MASLD, drafts hepatology e-consults, and answers drug-induced liver injury questions. Can liver-specific AI make a championship run? 👇 #HepMadness2026

In the next #TalkLiverToMe, experts revisit the fundamentals of hepatocellular carcinoma surveillance, with a practical look at patient selection, timing and the modalities available for early detection. Tune in this Wednesday on your Spotify, Apple Podcasts or EASL Campus to listen to this interactive discussion. More information: easl.eu/event/hepatocellular…

📑 The symptom burden of #PBC is substantial‼️ 🚨Fatigue: 51% 🚨Pruritus: 33% 🚨Severe Pruritus: 10% ⚠️Yet only 36% of patients with pruritus received treatment❕ ⭐️PBC care must extend beyond biochemical response❕ #LiverX #OpenAccess journals.lww.com/hepcomm/ful…

New kid on the block: get to know iLivTouch elastography journals.lww.com/hepcomm/ful…

It takes less than a minute to submit your picks! We’re 6 entries off breaking our all-time participation record! Submit your picks now! tourneytopia.com/aasld/hepma… @LiverFellow @AASLDtweets @ebtapper @jlouissaint89 #HepMadness2026 #TLM2026

"Follow the references: a game for nerds" Alt title - "Cost-effectiveness analysis is only as good as its inputs: a story in three pictures"

I once did a cost effectiveness analysis comparing shotgun vs deliberate testing for elevated ALT pubmed.ncbi.nlm.nih.gov/2771… @JHepatology We found that broad testing didn’t add much costs but increased false positives, especially when pretest probability of NAFLD was high

How to read a cost-effectiveness paper This is a powerful method. But poorly understood, often maligned. My goal is to improve critical appraisal and help good analyses get the appreciation they deserve 🧵#MedTwitter CEA: cost-effectiveness analysis

MELD tells us how sick the liver is. The #LiverFrailtyIndex tells us how sick the patient is. But LFI needs an in-person exam. New in @LTxJournal: the Lab-LFI. 7 proteins, c-stat 0.80 for predicting frailty in cirrhosis. Read it here: ovid.com/jnls/lt/fulltext/10…

🏀 Next up: Falls, Frailty, and Sarcopenia Sirisha Gaddipati explores how physical frailty, muscle loss, and fall risk affect outcomes in cirrhosis. Can this theme stand strong through the competition? 👇 #HepMadness2026

This one's for you, dad. @NEJM nejm.org/doi/full/10.1056/NE…

The best game in hepatology is back: HepMadness Fill out your bracket: tourneytopia.com/aasld/hepma…

Is there a better way to catch up on the most practice-changing hepatology research? 📚 1. Go to 🔗tourneytopia.com/aasld/hepma… 2. Click on each theme to read summaries of handpicked studies prepared by Team @LiverFellow 🔍 3. Pick the most influential, submit your bracket by Oct 31, and may the best research win! 🔥 #HepMadness2026 #MedEd @AASLDtweets @DBrandmanMD @Dr_NOvchinsky @Bubu_Banini @ruben_hernaez @ebtapper

This is the month I learned how to superimpose myself on a shared screen piped.video/QniIrUn-Sfo